IVLAV
CNTA

Index Venture Life Associates VI’s Centessa Pharmaceuticals CNTA Stock Holding History

Index Venture Life Associates VI’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,961,789
Closed -$396M – 1
2026
Q1 		$396M Hold
9,961,789
– – 100% 1
2025
Q4 		$249M Hold
9,961,789
– – 100% 1
2025
Q3 		$242M Hold
9,961,789
– – 100% 1
2025
Q2 		$131M Hold
9,961,789
– – 100% 1
2025
Q1 		$143M Hold
9,961,789
– – 100% 1
2024
Q4 		$167M Buy
+9,961,789
New +$165M 99.89% 1
2022
Q3 		$40M Hold
9,961,789
– – 100% 1
2022
Q2 		$48.5M Hold
9,961,789
– – 100% 1
2022
Q1 		$89.4M Hold
9,961,789
– – 100% 1
2021
Q4 		$112M Buy
+9,961,789
New +$134M 100% 1

Index Venture Life Associates VI's CNTA Position: Q2 2026 in Review

Index Venture Life Associates VI sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 9,961,789 shares — an estimated $396M sold.

Index Venture Life Associates VI first reported a position in CNTA in Q4 2021 and held it in 10 quarters. The position peaked at $396M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

  • Index Venture Life Associates VI reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Index Venture Life Associates VI sold 9,961,789 Centessa Pharmaceuticals shares in Q2 2026, an estimated $396M.
  • Index Venture Life Associates VI first reported a position in Centessa Pharmaceuticals in Q4 2021 and held it in 10 quarters.
  • Index Venture Life Associates VI's Centessa Pharmaceuticals position peaked at $396M in Q1 2026.
  • 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Index Venture Life Associates VI's 13F filing for Q2 2026.